In last trading session, Heron Therapeutics Inc. (NASDAQ:HRTX) saw 2.17 million shares changing hands with its beta currently measuring 0.99. Company’s recent per share price level of $1.21 trading at -$0.07 or -5.47% at ring of the bell on the day assigns it a market valuation of $167.05M. That closing price of HRTX’s stock is at a discount of -321.49% from its 52-week high price of $5.10 and is indicating a premium of 11.57% from its 52-week low price of $1.07. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.36 million shares which gives us an average trading volume of 1.88 million if we extend that period to 3-months.
For Heron Therapeutics Inc. (HRTX), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.80. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.29 in the current quarter.
Heron Therapeutics Inc. (NASDAQ:HRTX) trade information
Upright in the red during last session for losing -5.47%, in the last five days HRTX remained trading in the red while hitting it’s week-highest on Tuesday, 09/12/23 when the stock touched $1.21 price level, adding 9.7% to its value on the day. Heron Therapeutics Inc.’s shares saw a change of -51.60% in year-to-date performance and have moved -6.20% in past 5-day. Heron Therapeutics Inc. (NASDAQ:HRTX) showed a performance of -25.77% in past 30-days. Number of shares sold short was 25.32 million shares which calculate 12.69 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $7.75 to the stock, which implies a rise of 84.39% to its current value. Analysts have been projecting $5.00 as a low price target for the stock while placing it at a high target of $10.00. It follows that stock’s current price would drop -726.45% in reaching the projected high whereas dropping to the targeted low would mean a loss of -313.22% for stock’s current value.
Heron Therapeutics Inc. (HRTX) estimates and forecasts
Statistics highlight that Heron Therapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -49.37% of value to its shares in past 6 months, showing an annual growth rate of 34.73% while that of industry is 9.70. Apart from that, the company came raising its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to increase by 23.70% in the current quarter and calculating -64.70% decrease in the next quarter. This year revenue growth is estimated to rise 16.40% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $32.75 million for the same. And 4 analysts are in estimates of company making revenue of $32.94 million in the next quarter that will end on Dec 2023. Company posted $26.56 million and $30.03 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 23.30% while estimating it to be 9.70% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 14.50% during past 5 years. In 2023, company’s earnings growth rate is likely to be around 25.40% while estimates for its earnings growth in next 5 years are of 47.50%.
Heron Therapeutics Inc. is more likely to be releasing its next quarterly report in October and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.